Beam Therapeutics GAAP EPS of -$1.17 misses by $0.02, revenue of $14.27M beats by $0.14M

seekingalpha
2024-11-05
  • Beam Therapeutics press release (NASDAQ:BEAM): Q3 GAAP EPS of -$1.17 misses by $0.02.
  • Revenue of $14.27M (-17.0% Y/Y) beats by $0.14M.
  • Cash Position: Cash, cash equivalents and marketable securities were $925.8 million as of September 30, 2024, compared to $1.2 billion as of December 31, 2023.
  •  

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10